Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/7/2025 | $14.00 | Neutral → Buy | Rosenblatt |
1/31/2025 | $15.00 | Hold → Buy | Needham |
12/17/2024 | $8.00 → $9.50 | Equal-Weight → Underweight | Morgan Stanley |
11/19/2024 | $10.60 | Neutral | UBS |
6/26/2024 | $8.25 | Buy → Neutral | Rosenblatt |
5/3/2024 | $9.00 | Positive → Neutral | Susquehanna |
2/12/2024 | $10.00 → $13.00 | Hold → Buy | Stifel |
12/2/2022 | $12.00 | Hold | Stifel |
CHANDLER, Ariz., May 1, 2025 /PRNewswire/ -- VIAVI (NASDAQ:VIAV) today reported results for its third quarter ended March 29, 2025 with the following highlights. Third Quarter Net revenue of $284.8 million, up $38.8 million or 15.8% year-over-yearGAAP operating margin of 3.0%, up 780 bps year-over-yearNon-GAAP operating margin of 16.7%, up 740 bps year-over-yearGAAP net income of $19.5 million, up $44.1 million or 179.3% year-over-yearNon-GAAP net income of $33.9 million, up $20.7 million or 156.8% year-over-year GAAP diluted earnings per share (EPS) of $0.09, up $0.20 or 181.
CHANDLER, Ariz., April 17, 2025 /PRNewswire/ -- Viavi Solutions Inc. (VIAVI) (NASDAQ:VIAV) will announce its fiscal third quarter 2025 financial results for the period ended March 29, 2025, on Thursday, May 1, 2025, after the close of market. The Company will host an earnings call at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the call and the replay will be available on the VIAVI website at https://investor.viavisolutions.com. The quarterly earnings press release, supplementary slides and historical financial tables will be posted under the "Quarterly Results" section. To
CHANDLER, Ariz., Jan. 30, 2025 /PRNewswire/ -- VIAVI (NASDAQ:VIAV) today reported results for its second quarter ended December 28, 2024 with the following highlights. Second Quarter Net revenue of $270.8 million, up $16.3 million or 6.4% year-over-yearGAAP operating margin of 8.2%, down 60 bps year-over-yearNon-GAAP operating margin of 14.9%, up 170 bps year-over-yearGAAP net income of $9.1 million, down $1.6 million or 15.0% year-over-yearNon-GAAP net income of $29.4 million, up $5.7 million or 24.1% year-over-year GAAP diluted earnings per share (EPS) of $0.04, down $0.01 o
CHANDLER, Ariz., May 29, 2025 /PRNewswire/ -- VIAVI Solutions Inc. (VIAVI) (NASDAQ:VIAV) and 3-GIS, a market-leading fiber network design and management software provider, today announced a partnership to empower businesses with faster, more accurate fiber fault location capabilities, while also leveraging customers' existing Geographic Information System (GIS) investments. The combined solution, currently deployed at Windstream Wholesale, automates the current manual processes, offering significant advantages in improving network maintenance, minimizing downtime, increasing revenue and reducing cost. VIAVI, 3-GIS and Windstream will discuss this joint solution and its customer benefits in a
Solution enables cost-effective retrofitting of legacy systems with industry-leading PNT resilience CHANDLER, Ariz., May 28, 2025 /PRNewswire/ -- VIAVI Solutions Inc. (VIAVI) (NASDAQ:VIAV) today announced the launch of its second-generation RSR Transcoder, created to maintain operational capability in GPS/GNSS-denied, degraded or disrupted space operational environments (D3SOE). Globally, incidents of GPS and GNSS jamming and spoofing have surged as these tactics become a standard aspect of electronic warfare. While aimed at disrupting military operations, these hostile signal
First product validated at the VALOR lab's new RF-shielded anechoic chamber CHANDLER, Ariz., May 13, 2025 /PRNewswire/ -- VIAVI Solutions Inc. (VIAVI) (NASDAQ:VIAV) today announced that Metanoia Communications Inc.'s JURA Open Radio Unit (O-RU) has successfully completed end-to-end over-the-air (OTA) validation at the VIAVI Automated Lab-as-a-Service (VALOR™). It is the first product to be validated at the lab's new RF-shielded anechoic chamber to ensure compliance with O-RAN and 3GPP specifications. VALOR is an automated Lab-as-a-Service for Open RAN testing and is funded by
SC 13G - VIAVI SOLUTIONS INC. (0000912093) (Subject)
SC 13G/A - VIAVI SOLUTIONS INC. (0000912093) (Subject)
SC 13G/A - VIAVI SOLUTIONS INC. (0000912093) (Subject)
Joint Framework Expands Testing Services, Driving Industry-wide Adoption of Open RAN Solutions Advancing Industry Standards Through Collaboration: TIP partners with VIAVI to expand VALOR's testing for Open RAN.Streamlined Testing: Establishes VALOR as the first TIP-authorized test lab, reducing testing duplication.Industry-wide impact: Accelerates Open RAN adoption and drives global industry alignment.CHANDLER, Ariz., July 9, 2024 /PRNewswire/ -- Viavi Solutions Inc. (VIAVI) (NASDAQ:VIAV) and the Telecom Infra Project (TIP) today announced a strategic collaboration aimed at expanding the testing capabilities of the VIAVI Automated Lab-as-a-Service for Open RAN (VALOR™). VALOR, made possible
SCOTTSDALE, Ariz., Feb. 18, 2021 /PRNewswire/ -- (NASDAQ: VIAV) Viavi Solutions Inc. ("VIAVI") announced today the appointment of Henk Derksen as Executive Vice President and Chief Financial Officer effective March 15, 2021. Mr. Derksen will report to President and Chief Executive Officer Oleg Khaykin and oversee the global finance organization, including finance, accounting and reporting, tax, treasury, internal audit, investor relations and information technology (IT). "I'm excited to have Henk join our executive team and help us execute our growth strategy." said Oleg Khaykin. "He brings extensive financial, international, and business management expertise to VIAVI, has deep familiarit
8-K - VIAVI SOLUTIONS INC. (0000912093) (Filer)
SCHEDULE 13G/A - VIAVI SOLUTIONS INC. (0000912093) (Subject)
144 - VIAVI SOLUTIONS INC. (0000912093) (Subject)
4 - VIAVI SOLUTIONS INC. (0000912093) (Issuer)
3 - VIAVI SOLUTIONS INC. (0000912093) (Issuer)
4 - VIAVI SOLUTIONS INC. (0000912093) (Issuer)
Rosenblatt upgraded Viavi from Neutral to Buy and set a new price target of $14.00
Needham upgraded Viavi from Hold to Buy and set a new price target of $15.00
Morgan Stanley downgraded Viavi from Equal-Weight to Underweight and set a new price target of $9.50 from $8.00 previously